Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | TSHR | P16473 | 2/20 | 0.73 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18948462 | 0.86 | LMNA (0.69) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL14485108 | 0.85 | SMN1; SMN2 (1.00) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL19156970 | 0.80 | LMNA (0.62) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL15838864 | 0.77 | MAPT (0.67) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL20083913 | 0.77 | LMNA (0.68) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL15838841 | 0.76 | ALDH1A1 (0.66) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL19157296 | 0.76 | LMNA (0.64) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL30926499 | 0.75 | LMNA (0.76) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL27179489 | 0.75 | LMNA (0.76) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL14485232 | 0.74 | MAPT (0.82) | SMN1; SMN2LMNAMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196376-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196376-B2 | Hepatitis B antiviral agents | HAVCR2, EIF2AK2, IRF3 | SMN1; SMN2 4356/4885LMNA 3521/4885MEN1 4246/4885 |
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | SMN1; SMN2 4356/4885LMNA 3521/4885MEN1 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.